Our science

Abstracts

Pharmacokinetics of RLS-0071, a Novel Anti-Inflammatory Peptide, in Newborns With Moderate or Severe Hypoxic Ischemic Encephalopathy

Pediatric Academic Societies 2025 Annual Meeting

Abstract

Background: Hypoxic ischemic encephalopathy (HIE) is a common cause of mortality and life-long disabilities. RLS-0071 is a novel anti-inflammatory peptide that inhibits complement activation at C1, as well as myeloperoxidase activity and extracellular trap formation. PK analysis of RLS-0071 in animal and adult human studies demonstrate a two-compartment model with a bi-exponential decline in plasma concentration driven by rapid distribution into tissues. RLS-0071 is currently being evaluated in a phase 2 clinical trial of neonates with moderate or severe HIE.

Objective: Assess the PK profile of RLS-0071 in HIE babies for safety.

Methods: STAR is a phase 2 randomized placebo-controlled dose-escalation trial (NCT05778188) at 13 NICUs in the USA. After informed consent, RLS-0071 was administered within 10 hours of birth at 3 mg/kg IV (first dosing cohort) and continued every 8 hours for a total of 10 doses. Blood samples were obtained pre-dose, end of first infusion (Cmax), 1 hour post dose (at the inflection point in the bi-exponential kinetics) and at 8 hours post dose (Cmin). Plasma samples were processed to isolate the peptide prior to measurement by LC/MS (Bioagilytix).

Neonatal PK modeling was performed using a 2-compartment model and results compared against adult PK profiles derived in a different clinical trial (NCT05298787). To simulate a pediatric population, an adult model was adapted with 30% variability in clearance (CL) and volume of distribution (Vd). This model was then applied to neonates weighing 3 kg, with 100 simulations performed by sampling from the ETA distributions of the PK parameters. Simulations were conducted using allometric scaling and assumed a conservative 50% reduction in CL to account for delayed organ maturation and hypothermia.

Results: RLS-0071 plasma concentrations were obtained for 10 HIE neonates (8 moderate, 2 severe) and summarized in Table 1. HIE infant PK curves for RLS-0071 at the 3 mg/kg/dose were similar to adult human curves at the 2 mg/kg/dose (Figure 1) and within established safe plasma levels in adults. No drug accumulation was observed. Simulation results predicted that 30% of infants receiving a dose of 3 mg/kg would reach the target peak concentration (Cmax = 17 mcg/ml), associated with optimal efficacy in the animal model (Table 2).

Conclusions: The kinetics of RLS-0071 were bi-exponential and fell within previously established safety limits. These results are reassuring for the continued clinical trials of RLS-0071 in HIE. Additional analysis is planned for higher dosing cohorts.

More Abstracts

Aug 20, 2020

Incompatible Erythrocyte Transfusion With Lipopolysaccharide Induces Acute Lung Injury...

Acute transfusion reactions can manifest in many forms including acute hemolytic transfusion reaction, allergic reaction and transfusion-related...

Read More
Mar 28, 2018

Inhibition of Immune Complex Complement Activation And Neutrophil Extracellular...

Abstract: Two major aspects of systemic lupus erythematosus (SLE) pathogenesis that have yet to be targeted therapeutically are immune complex-i...

Read More
Dec 31, 2019

Inhibition of Complement Activation, Myeloperoxidase, NET Formation And Oxidant...

A product of rational molecular design, PA-dPEG24 is the lead derivative of the PIC1 family of peptides with multiple functional abilities inclu...

Read More